Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. Through the transaction, Lantheus has acquired OCTEVY, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate PNT2003, as well as a portfolio of clinical and pre-clinical theranostic pairs. The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lantheus price target lowered to $122 from $127 at B. Riley
- Lantheus CFO Marshall sells 10,000 common shares
- Lantheus Holdings Inc. Reports Strong Growth and Strategic Moves
- Lantheus Holdings Faces Uncertainty Amid Potential PET Scanner Shortage
- Lantheus: Strong Financial Performance and Strategic Positioning Drive Buy Rating